With more than 30 million patients with diabetes and only 6000 endocrinologists, that primary care doctor is playing a crucial role in seeing diabetics, said Jaime A. Davidson, MD, FACP, MACE, professor of medicine, Touchstone Diabetes Center, The University of Texas Southwestern Medical Center.
With more than 30 million patients with diabetes and only 6000 endocrinologists, that primary care doctor is playing a crucial role in seeing diabetics, said Jaime A. Davidson, MD, FACP, MACE, professor of medicine, Touchstone Diabetes Center, The University of Texas Southwestern Medical Center.
Transcript
What are the challenges that social determinants of health present in diabetes management?
Well one of the challenges is actually to get the patients to be seen on a timely basis. At least in endocrinology we have about 6000 endocrinologists. But not every endocrinologist is willing to see patients with diabetes. We have over 30 million patients with diabetes. So, they need to be seen by the primary care [doctor], and you know in primary care today they actually need to see 40, 50 patients a day. You cannot be fair to a patient with diabetes on a 5-minute visits, because it’s not just glucose—it’s lipids, it’s hypertension, it’s looking at the eyes, looking at the feet. So, the system has to change and allow more time to a doctor who sees patients with diabetes. And that’s one of the big challenges.
The other big challenge is medications that change on a yearly basis, sometimes more than once a year. Supplies that change and they cannot get them. For example, if someone is taking an SGLT2 inhibitor called one name, and all of a sudden, they get to the pharmacy and their care plan doesn’t cover that anymore, it covers something else, the patient gets confused. Sometimes we don’t get a call until 2 months later. So, for a period of time, the patient may not be able to take the medications properly. In insulin, that’s very common.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More